Comprehensive Cell Solutions (CCS) has been pioneering advances in the research, development, and manufacture of cell therapies: A business unit of New York Blood Center Enterprises (NYBCe), CCS is a cell and gene therapy-focused development and manufacturing organization that provides critical capacity to an underserved population of early-stage developers, as well as expertise and a strategic footprint for hospital treatment centers and pharmaceutical organizations. For more than 20 years, CCS has been pioneering advances in the research, development, and manufacture of cell therapies, providing: - Unmatched procurement of apheresis and cord blood products - Access to our expansive network of NYBCe resources - Robust process and analytical development - Regulatory consulting across all phases of development - Skilled staff and ready capacity at our accredited facilities - Collaborative, end-to-end partners In 2023, CCS announced the acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas, and Louisville, Kentucky. The acquisition of both locations, combined with our vast cell sourcing and collection network, accelerates the delivery of fully integrated vein-to-vein cell and gene therapy development and manufacturing solutions for the continental United States (US), capable of serving the biopharma industry and large hospital systems. Visit our website to learn more and connect with us!